N-ethyl-N'-[4-[4-[4-[[(E)-4-[4-[4-[4-[4-(ethylamino)butylamino]butylamino]butylamino]butylamino]but-2-enyl]amino]butylamino]butylamino]butyl]butane-1,4-diamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-ethyl-N'-[4-[4-[4-[[(E)-4-[4-[4-[4-[4-(ethylamino)butylamino]butylamino]butylamino]butylamino]but-2-enyl]amino]butylamino]butylamino]butyl]butane-1,4-diamine
• 化学式: C₄₀H₉₀N₁₀
• 分子量: 711.2
• InChiKey: BDTMNIXVRYGYPA-QURGRASLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  50
• 可旋转键数：
  46
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  120
• 氢给体数：
  10
• 氢受体数：
  10

文献信息

• Use of polyamines in compositions and methods for inducing or promoting skin darkening and regulating melanogenesis
  申请人：Agency for Science, Technology and Research

  公开号：US11219588B2

  公开（公告）日：2022-01-11

  The present disclosure provides a method of inducing or promoting darkening of the skin and/or melanogenesis, a method of treating a skin condition or disorder, in particular hypopigmentation, comprising administration of a polycationic aliphatic amine, wherein said polycationic aliphatic amine preferably is putrescine, spermidine and spermine. The invention further includes corresponding methods of reducing or preventing darkening of skin and/or melanogenesis, or related methods of treating a skin condition or disorder, comprising administration of at least an inhibitor of polycationic aliphatic amine transport or synthesis, wherein said inhibitor is preferably trimer44NMe or difluoromethylornithine (DFMO) respectively.

  本发明公开了一种诱导或促进皮肤变黑和/或黑色素生成的方法，一种治疗皮肤状况或疾病，特别是色素沉着的方法，包括施用多阳离子脂肪族胺，其中所述多阳离子脂肪族胺优选为腐胺、精胺和精胺。本发明还包括减少或预防皮肤变黑和/或黑色素生成的相应方法，或治疗皮肤状况或疾病的相关方法，包括施用至少一种多阳离子脂族胺转运或合成抑制剂，其中所述抑制剂最好分别为三聚44NMe或二氟甲基鸟氨酸（DFMO）。
• Use of N1,N4-bis[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine Compounds in Combination with Epigenetic-Acting Pharmaceuticals for Enhanced Cancer Therapy
  申请人：Marton Laurence

  公开号：US20130102556A1

  公开（公告）日：2013-04-25

  Combination methods for treatment of cancer and of blood disorders, using PG-11047 ((2Z)-N1,N4-bis[3-(ethy-lammo) propyl]-2-butene-1,4-diamine) and PG-11048 ((2E)-N1,N4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine) in combination with DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, or both DNA methyltransferase inhibitors and histone deacetylase inhibitors, are disclosed. Hematopoietic cancers, lung cancers, mesothelioma, cutaneous T-cell lymphoma (CTCL), multiple myeloma, solid tumors, and blood disorders such as myelodysplastic syndromes can be treated using the methods of the invention.
• Use of Polyamines in Compositions and Methods for Inducing or Promoting Skin Darkening and Regulating Melanogenesis
  申请人：Agency for Science, Technology and Research

  公开号：US20190216702A1

  公开（公告）日：2019-07-18

  The present disclosure provides a method of inducing or promoting darkening of the skin and/or melanogenesis, a method of treating a skin condition or disorder, in particular hypopigmentation, comprising administration of a polycationic aliphatic amine, wherein said polycationic aliphatic amine preferably is putrescine, spermidine and spermine. The invention further includes corresponding methods of reducing or preventing darkening of skin and/or melanogenesis, or related methods of treating a skin condition or disorder, comprising administration of at least an inhibitor of polycationic aliphatic amine transport or synthesis, wherein said inhibitor is preferably trimer44NMe or difluoromethylornithine (DFMO) respectively.